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e1 previously reported that a 10-year-old boy with
primary pulmonary hypertension, defined as idio-
pathic pulmonary arterial hypertension (IPAH), un-
derwent successful right single lobe transplantation
using his mother’s right lower lobe. The dramatic improvement of
his pulmonary hemodynamics was maintained through a 6-month
follow-up period. However, long-term durability of hemodynamics
as the boy grows remains a major unresolved issue. The IPAH pa-
tient has been carefully observed for more than 6 years with regular
evaluation of lung and cardiac function. In this article, we present
the long-term results of cardiopulmonary function of the growing
boy who received a mature adult single lobe.
Clinical Summary
The details of the patient’s clinical course were described in our pre-
vious report.1 In brief, a 10-year-old boy with IPAH underwent right
single lobe transplantation using the right lower lobe from his 38-
year-old mother. The forced vital capacity (FVC) of the graft was
estimated to be 882 mL, or 52.3% of the recipient’s predicted
FVC, which we considered to be acceptable for transplantation on
the basis of the data of unilateral cadaveric lung transplantation
(CLT) for IPAH.2 Despite high-dose epoprostenol therapy, his
mean pulmonary arterial pressure was 59 mm Hg. His height and
weight were 122 cm and 19.6 kg at the time of transplantation. After
right single lobe transplantation with cardiopulmonary bypass, re-
markable improvement in pulmonary hemodynamics was obtained.
He was discharged from the hospital without supplementary oxygen
on postoperative day 43. Postoperative immunosuppression con-
sisted of cyclosporine, azathioprine, and prednisone.
Routine full postoperative assessment including right heart
catheterization, complete pulmonary function test, arterial blood
gas analysis, and differential ventilation/perfusion lung scan was
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5 years (Table 1). During the 5-year period, he has grown 27 cm
in height and 21.4 kg in weight. His vital capacity (VC) and forced
expiratory volume in 1 second (FEV1) have nearly doubled (VC,
from 1170 mL to 2310 mL; FEV1, from 1020 mL to 1840 mL).
The transplanted lobe received about 56% of ventilation and 80%
of perfusion throughout the observation period. The dramatic
improvement in pulmonary hemodynamics has been well main-
tained for 5 years (mean pulmonary arterial pressure at 5-year fol-
low-up, 20 mmHg). He has been classified in World Health
Organization class I and has been able to carry out normal activities
as a student for more than 6 years since he received the single lobe
transplant.
Discussion
Living-donor lobar lung transplantation (LDLLT) was pioneered by
the University of Southern California group to deal with the shortage
of cadaveric donors.3 IPAH is one of the diseases for which bilateral
LDLLT can be applied when medical treatment fails to control the
disease.4 Unilateral CLT has been recognized as one of the optimal
surgical options for IPAH, even for children who are expected to
grow, and has demonstrated acceptable long-term outcome.2 For
our present pediatric case, living-donor single lobe transplantation
was the only realistic option because obtaining cadaveric donors
is extremely difficult in Japan. There were obvious concerns regard-
ing whether pulmonary hypertension would recur in the single ma-
tured lobe when it received most of the patient’s cardiac output as
the boy grew.
Although he grew considerably, 27 cm in height, he maintained
normal pulmonary hemodynamics throughout the observation pe-
riod. VC and FEV1 gradually increased whereas the ratios of perfu-
sion and ventilation to the transplanted lobe were stable. These
findings strongly suggested that the transplanted matured lobe
also grew in the growing recipient during the observation period.
Regarding pulmonary function after transplantation, Sritippaya-
wan and colleagues5 reported that increasing lung volume occurred
in immature recipients of CLT and LDLLT by alveolar dilation
(lung dilation) rather than alveolization (lung growth) that conse-
quently increases alveolar capillary. On the basis of these findings,
alveolar dilation may not only cause increased lung volume but also
may help pulmonary hemodynamic stabilization, preventing devel-
opment of unbalanced left/right proportions in ventilation–perfusion
and pulmonary hypertension. Of note, the growth of mature lobes
by pneumocyte division has also been reported in an animal model,
implying conflicting results.5,6
In conclusion, our experience suggests that living-donor single
lobe transplantation is an acceptable option for selected children
with severe IPAH in the situations of limited donor supply.oracic and Cardiovascular Surgery c Volume 135, Number 2 451
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After transplant
Before transplant 6 mo 1 y 3 y 5 y
Height (cm) 122 125 129.5 140 149
Weight (kg) 19.6 24.2 25.1 30.0 41.0
PAP (mm Hg) 85/40 (59) 38/12 (22) 32/6 (17) 40/8 (20) 41/8 (21)
PCWP (mm Hg) 8 10 3 5 8
CVP (mm Hg) 9 3 0 2 3
CI (L $ min21 $ m22) 2.7 4.3 4.0 3.8 4.1
PaO2 (mm Hg) 91.0 (with O2) 99.7 99.3 95.2 108.9
PaCO2 (mm Hg) 38.7 30.7 33.7 36.5 35.2
VC (mL) 1170 1410 1590 1890 2310
%VC (%) 69.6 78.3 82.8 79.4 63.6
FEV1 (mL) 1020 1030 1270 1610 1840
FEV1.0% (%) 88.7 78.0 81.9 81.7 79.7
Ventilation
Right (%) 61.1 56.9 56.7 59.1 55.5
Left (%) 38.9 43.1 43.3 40.9 44.5
Perfusion
Right (%) 61.8 81.6 77.0 78.3 81.1
Left (%) 38.2 18.4 23.0 21.7 18.9
WHO class III I I I I
PAP, Pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; CVP, central venous pressure; CI, cardiac index; PaO2, arterial oxygen tension;
PaCO2, arterial carbon dioxide tension; VC, vital capacity; FEV1, forced expiratory volume in 1 second; WHO, World Health Organization.References
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